Advertisement
Singapore markets close in 1 hour 40 minutes

  • Straits Times Index

    3,270.32
    +45.15 (+1.40%)
     

  • Nikkei

    37,552.16
    +113.55 (+0.30%)
     

  • Hang Seng

    16,802.97
    +291.28 (+1.76%)
     

  • FTSE 100

    8,065.29
    +41.42 (+0.52%)
     

  • Bitcoin USD

    66,376.62
    +194.07 (+0.29%)
     

  • CMC Crypto 200

    1,399.08
    -15.68 (-1.11%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • Dow

    38,239.98
    +253.58 (+0.67%)
     

  • Nasdaq

    15,451.31
    +169.30 (+1.11%)
     

  • Gold

    2,317.60
    -28.80 (-1.23%)
     

  • Crude Oil

    83.02
    +0.17 (+0.21%)
     

  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     

  • FTSE Bursa Malaysia

    1,563.66
    +4.07 (+0.26%)
     

  • Jakarta Composite Index

    7,117.06
    +43.24 (+0.61%)
     

  • PSE Index

    6,506.80
    +62.72 (+0.97%)
     

Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?

Zacks Equity Research

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Zoetis (ZTS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Zoetis is one of 889 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ZTS is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for ZTS's full-year earnings has moved 2.64% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

ADVERTISEMENT

According to our latest data, ZTS has moved about 50.19% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 1.55% on average. This shows that Zoetis is outperforming its peers so far this year.

To break things down more, ZTS belongs to the Medical - Drugs industry, a group that includes 178 individual companies and currently sits at #56 in the Zacks Industry Rank. Stocks in this group have gained about 0.10% so far this year, so ZTS is performing better this group in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to ZTS as it looks to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Zoetis Inc. (ZTS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research